Remus Pharmaceuticals Limited — Others, 27-03-2025: Trading Window

Remus Pharmaceuticals Limited has announced a trading window closure for its Directors, Promoters, Designated Persons, and their immediate relatives, effective from April 1, 2025, until 48 hours after the release of the audited financial results for the half-year and financial year ending March 31, 2025. This move aligns with the company's internal policies and aims to prevent insider trading during this critical financial reporting period.

Investors should note that this could lead to a cautious sentiment as trading is restricted, but it underscores the company’s commitment to transparency and governance. Overall, it suggests a proactive approach to compliance, which may be viewed positively by stakeholders.